S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NYSE:DYN

Dyne Therapeutics (DYN) Stock Forecast, Price & News

$9.09
-0.18 (-1.94%)
(As of 09/22/2023 ET)
Compare
Today's Range
$8.91
▼
$9.36
50-Day Range
$9.09
▼
$12.18
52-Week Range
$8.04
▼
$15.60
Volume
292,696 shs
Average Volume
497,019 shs
Market Capitalization
$554.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.20
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media

Dyne Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
199.2% Upside
$27.20 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.10mentions of Dyne Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$72,073 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.57) to ($3.18) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

279th out of 963 stocks

Pharmaceutical Preparations Industry

116th out of 458 stocks

See Top Rated MarketRank™ Stocks Here

DYN stock logo

About Dyne Therapeutics (NYSE:DYN) Stock

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

DYN Price History

DYN Stock News Headlines

September 22, 2023 | marketwatch.com
Dyne Therapeutics Gets New FDA Orphan Drug Designation
September 22, 2023 | markets.businessinsider.com
Dyne Therapeutics's DYNE-101 Gets Orphan Drug Designation From FDA
September 24, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
September 22, 2023 | msn.com
Dyne Therapeutics gets FDA orphan drug status for DM1 drug
September 22, 2023 | americanbankingnews.com
Dyne Therapeutics (NYSE:DYN) Shares Down 6.3% After Insider Selling
September 20, 2023 | finance.yahoo.com
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
September 18, 2023 | markets.businessinsider.com
Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
September 15, 2023 | finance.yahoo.com
Why Shares of Dyne Therapeutics Fell This Week
September 24, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
September 14, 2023 | finance.yahoo.com
Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics Inc
September 10, 2023 | msn.com
Dyne Therapeutics: Muscle Disease Oligo Therapy Developer In Early Stages
September 5, 2023 | finance.yahoo.com
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
August 24, 2023 | finance.yahoo.com
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
August 10, 2023 | msn.com
JP Morgan Maintains Dyne Therapeutics (DYN) Overweight Recommendation
August 3, 2023 | seekingalpha.com
Dyne Therapeutics GAAP EPS of -$1.08
August 3, 2023 | finance.yahoo.com
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
June 30, 2023 | markets.businessinsider.com
Parent Project Muscular Dystrophy Hosts 29th Annual Conference in Dallas, Texas
June 16, 2023 | finance.yahoo.com
‘SMID Caps Are Poised for a Good Run,’ Says Oppenheimer — And These 2 Stocks Fit the Bill With Over 100% Upside
June 1, 2023 | finance.yahoo.com
Dyne Therapeutics to Present at Jefferies Healthcare Conference
May 28, 2023 | msn.com
Dyne Therapeutics: FORCE Platform Poised To Revolutionize Gene Therapy
May 25, 2023 | msn.com
Dyne's muscle disorder therapy DYNE-101 gets orphan drug status in EU
May 25, 2023 | markets.businessinsider.com
Dyne Therapeutics' DYNE-101 Granted Orphan Drug Designation By EMA
May 25, 2023 | finance.yahoo.com
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
May 17, 2023 | finance.yahoo.com
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
May 17, 2023 | finance.yahoo.com
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
May 11, 2023 | finanznachrichten.de
Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023 | msn.com
Dyne Therapeutics: Q1 Earnings Insights
See More Headlines
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DYN Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:DYN
CUSIP
N/A
CIK
1818794
Web
www.dyne-tx.com
Phone
781-786-8230
Fax
781-786-8866
Employees
134
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.20
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+199.2%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-168,100,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-79.63%
Return on Assets
-66.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.54
Quick Ratio
10.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.84 per share
Price / Book
1.88

Miscellaneous

Outstanding Shares
61,020,000
Free Float
40,951,000
Market Cap
$554.67 million
Optionable
Optionable
Beta
0.16
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Joshua T. Brumm (Age 45)
    CEO, Pres & Director
    Comp: $946.5k
  • Ms. Susanna Gatti High M.B.A. (Age 55)
    Chief Operating Officer
    Comp: $655.5k
  • Dr. Oxana Beskrovnaya Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $631.08k
  • Dr. Romesh Subramanian Ph.D. (Age 58)
    Co-Founder & Advisor
  • Mr. Richard William Scalzo M.B.A. (Age 36)
    Sr. VP and Head of Fin. & Admin.
  • Mr. John Najim M.B.A.
    Chief Technical Officer
  • Ms. Amy Reilly (Age 49)
    Sr. VP and Head of Corp. Communications & Investor Relations
  • Mr. Daniel Wilson (Age 51)
    Sr. VP & Head of Legal
  • Ms. Kate Mitchell
    VP & Head of HR
  • Ms. Debra Feldman (Age 52)
    Chief Regulatory Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













DYN Stock - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
View DYN analyst ratings or view top-rated stocks.

What is Dyne Therapeutics' stock price forecast for 2023?

5 Wall Street analysts have issued 12-month price objectives for Dyne Therapeutics' shares. Their DYN share price forecasts range from $20.00 to $34.00. On average, they anticipate the company's share price to reach $27.20 in the next year. This suggests a possible upside of 199.2% from the stock's current price.
View analysts price targets for DYN or view top-rated stocks among Wall Street analysts.

How have DYN shares performed in 2023?

Dyne Therapeutics' stock was trading at $11.59 at the beginning of the year. Since then, DYN shares have decreased by 21.6% and is now trading at $9.09.
View the best growth stocks for 2023 here.

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DYN earnings forecast.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NYSE:DYN) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.81) by $0.27.

What ETFs hold Dyne Therapeutics' stock?

ETFs with the largest weight of Dyne Therapeutics (NYSE:DYN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Dyne Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyne Therapeutics investors own include iShares Preferred and Income Securities ETF (PFF), Micron Technology (MU), IVERIC bio (OPHT), SentinelOne (S), Starbucks (SBUX), SunPower (SPWR), Apollo Investment (AINV), Argos Therapeutics (ARGSQ), Broadcom (AVGO) and Bausch Health Companies (BHC).

When did Dyne Therapeutics IPO?

(DYN) raised $175 million in an initial public offering on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

What is Dyne Therapeutics' stock symbol?

Dyne Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DYN."

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.44%), Deep Track Capital LP (4.10%), Wasatch Advisors LP (3.70%), VR Adviser LLC (3.56%), Goldman Sachs Group Inc. (3.29%) and Franklin Resources Inc. (3.14%). Insiders that own company stock include Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Richard William Scalzo, Susanna Gatti High and Wildon Farwell.
View institutional ownership trends.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dyne Therapeutics' stock price today?

One share of DYN stock can currently be purchased for approximately $9.09.

How much money does Dyne Therapeutics make?

Dyne Therapeutics (NYSE:DYN) has a market capitalization of $554.67 million. The company earns $-168,100,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis.

How many employees does Dyne Therapeutics have?

The company employs 134 workers across the globe.

How can I contact Dyne Therapeutics?

Dyne Therapeutics' mailing address is 1560 Trapelo Road, Waltham, MA 02451, United States. The official website for the company is www.dyne-tx.com. The company can be reached via phone at 781-786-8230, via email at ir@dyne-tx.com, or via fax at 781-786-8866.

This page (NYSE:DYN) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -